Global Pneumococcal Conjugate Vaccine (PCV) Market Report, History and Forecast 2024-2034, Breakdown Data by Companies, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Pneumococcal Conjugate Vaccine (PCV) Market Report, History and Forecast 2024-2034, Breakdown Data by Companies, Key Regions, Types and Application
Pneumococcal Conjugate Vaccine (PCV) report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Pneumococcal Conjugate Vaccine (PCV) market is projected to reach US$ 5142.8 million in 2034, increasing from US$ 4138 million in 2022, with the CAGR of 3.2% during the period of 2024 to 2034. Demand from Child and Adult are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Pneumococcal Conjugate Vaccine (PCV) industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Pneumococcal Conjugate Vaccine (PCV) key companies include Pfizer, GSK, Sanofi, Merck, Walvax Biotechnology, Royal (Wuxi) Bio-Pharmaceutical, Zhifei Biologic and Serum Institute of India, etc. Pfizer, GSK, Sanofi are top 3 players and held % share in total in 2022.
Pneumococcal Conjugate Vaccine (PCV) can be divided into 23-valent Vaccine, 10-valent Vaccine, 7-valent Vaccine and 13-valent Vaccine, etc. 23-valent Vaccine is the mainstream product in the market, accounting for % share globally in 2022.
Pneumococcal Conjugate Vaccine (PCV) is widely used in various fields, such as Child and Adult, etc. Child provides greatest supports to the Pneumococcal Conjugate Vaccine (PCV) industry development. In 2022, global % share of Pneumococcal Conjugate Vaccine (PCV) went into Child filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Pneumococcal Conjugate Vaccine (PCV) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
Pfizer
GSK
Sanofi
Merck
Walvax Biotechnology
Royal (Wuxi) Bio-Pharmaceutical
Zhifei Biologic
Serum Institute of India
Segment by Type
23-valent Vaccine
10-valent Vaccine
7-valent Vaccine
13-valent Vaccine
Child
Adult
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Pneumococcal Conjugate Vaccine (PCV) market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2024-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Pneumococcal Conjugate Vaccine (PCV) introduction, etc. Pneumococcal Conjugate Vaccine (PCV) Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Pneumococcal Conjugate Vaccine (PCV) market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
North America, Europe and Asia Pacific are the key regions for Pneumococcal Conjugate Vaccine (PCV) industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Pneumococcal Conjugate Vaccine (PCV) key companies include Pfizer, GSK, Sanofi, Merck, Walvax Biotechnology, Royal (Wuxi) Bio-Pharmaceutical, Zhifei Biologic and Serum Institute of India, etc. Pfizer, GSK, Sanofi are top 3 players and held % share in total in 2022.
Pneumococcal Conjugate Vaccine (PCV) can be divided into 23-valent Vaccine, 10-valent Vaccine, 7-valent Vaccine and 13-valent Vaccine, etc. 23-valent Vaccine is the mainstream product in the market, accounting for % share globally in 2022.
Pneumococcal Conjugate Vaccine (PCV) is widely used in various fields, such as Child and Adult, etc. Child provides greatest supports to the Pneumococcal Conjugate Vaccine (PCV) industry development. In 2022, global % share of Pneumococcal Conjugate Vaccine (PCV) went into Child filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Pneumococcal Conjugate Vaccine (PCV) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
By Company
Pfizer
GSK
Sanofi
Merck
Walvax Biotechnology
Royal (Wuxi) Bio-Pharmaceutical
Zhifei Biologic
Serum Institute of India
Segment by Type
23-valent Vaccine
10-valent Vaccine
7-valent Vaccine
13-valent Vaccine
Segment by Application
Child
Adult
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Pneumococcal Conjugate Vaccine (PCV) market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2024-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Pneumococcal Conjugate Vaccine (PCV) introduction, etc. Pneumococcal Conjugate Vaccine (PCV) Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Pneumococcal Conjugate Vaccine (PCV) market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices